Equillium (STU:0FY) Change In Receivables : €-1.50 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Change In Receivables?

Equillium's change in receivables for the quarter that ended in Mar. 2024 was €-1.21 Mil. It means Equillium's Accounts Receivable increased by €1.21 Mil from Dec. 2023 to Mar. 2024 .

Equillium's change in receivables for the fiscal year that ended in Dec. 2023 was €-0.82 Mil. It means Equillium's Accounts Receivable increased by €0.82 Mil from Dec. 2022 to Dec. 2023 .

Equillium's Accounts Receivable for the quarter that ended in Mar. 2024 was €4.64 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Equillium's Days Sales Outstanding for the three months ended in Mar. 2024 was 43.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Equillium's liquidation value for the three months ended in Mar. 2024 was €12.48 Mil.

Equillium Change In Receivables Historical Data

The historical data trend for Equillium's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Change In Receivables Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-2.68

-0.82

Equillium Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.55	-0.29	-0.02	0.03	-1.21

Equillium Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.50 Mil.

Equillium (STU:0FY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Equillium's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.644	/	9.834	*	91
=	43.09

2. In Ben Graham's calculation of liquidation value, Equillium's accounts receivable are only considered to be worth 75% of book value:

Equillium's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	29.702	-	20.703	+	0.75 * 4.644	+	0.5 * 0
=	12.48

Equillium Change In Receivables Related Terms

Thank you for viewing the detailed overview of Equillium's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (STU:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (STU:0FY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EQ:USA

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (STU:0FY) Headlines

No Headlines